Built with implementation partner SmartOSC, and Backbase Expert Services, the app targets 200,000 new customers a month through fully self-serve onboarding.

HANOI, VIETNAM - Media OutReach Newswire - 29 September 2026 - Vietnam Maritime Commercial Joint Stock Bank (MSB) announced the official launch of MSB's new digital banking apps for retail and enterprise customers. The apps went live at a launch event held in MSB's new headquarters building in Hanoi, bringing together around 200 guests, including bank leadership, Backbase, and implementation partner SmartOSC.

Two Apps, One Unified Platform

Most banks run separate platforms for retail and enterprise customers. MSB built two apps on one platform to close that gap, giving both customer groups one consistent experience instead of two disconnected ones. The redesign was based on customer research, market analysis, and the pain points customers raised on the bank's previous platform, checked against compliance and governance requirements throughout.

On the retail side, the app introduces Security Hub, a set of features built to protect customer accounts, alongside end-to-end lending journeys designed for customers who are new to the bank. Customers can manage daily banking, credit cards, and loyalty rewards from a single app, with full visibility and control over their transaction history and the ability to export it on demand. The enterprise app mirrors that approach, connecting non-credit and credit journeys into one flow instead of the paperwork-heavy process business customers dealt with before.

Built to scale

MSB expects the apps to bring in 200,000 new retail customers and 500 new enterprise customers a month through its self-serve onboarding journeys. The bank has redesigned close to 40 end-to-end customer journeys and digitized 70% of its internal processes as part of the rollout.

MSB chose Backbase for the flexibility of the platform and the ability to shape it around MSB's own targets rather than a fixed setup. MSB's experience with Backbase's AI-native Banking OS gave it the confidence to scale further, and SmartOSC's local team brought the market knowledge and hands-on support needed to hit the tight deadline as one team with MSB and Backbase. Backbase Expert Services provided platform guidance, design principles, and best practices to ensure scalable platform adoption.

"We built these apps to bring the future of finance to our customers. Retail and enterprise customers now get one consistent experience, from their first transaction to their most complex banking need. That's the standard we set for ourselves, and the standard we want MSB to be known for in Vietnam."

Mr. Vu Ngoc Bong Lai, Head of Strategy and Innovation Division, at MSB.

"Vietnam's digital economy is one of the fastest-growing in Southeast Asia, and a handful of banks are setting the pace for what digital banking there can become. MSB looked at that shift and decided to lead it. They came to us with a clear ambition: unify retail and enterprise banking on one platform, on an aggressive timeline. Today, they are live with both. For Backbase, it confirms that the AI-native Banking OS gives a bank a real foundation to build on, so their teams spend time on what sets them apart, not on rebuilding what's already there."

Abhijit Chavan, Senior Vice President, Asia & ANZ, at Backbase.

"Digital transformation is ultimately about turning technology into meaningful experiences and sustainable business value. Working alongside MSB and Backbase, SmartOSC is proud to contribute the implementation expertise and delivery capabilities needed to bring this vision to life. This launch demonstrates what can be achieved when business ambition, technology, and execution come together as one team."

Mr. Alex Nguyen, Senior Vice President, at SmartOSC.

Backbase

Backbase built the AI-native Banking OS - the operating system that turns fragmented banking operations into a Unified Frontline. Customers, employees, and AI agents work as one across digital channels, front-office, and operations.

Backbase was founded in 2003 by Jouk Pleiter and is headquartered in Amsterdam, with teams across North America, Europe, the Middle East, Asia-Pacific, Africa and Latin America. 120+ leading banks run on Backbase across Retail, SMB & Commercial, Private Banking, and Wealth Management.

Vietnam Maritime Commercial Joint Stock Bank (MSB)

Vietnam Maritime Commercial Joint Stock Bank (MSB) was established in 1991 as Vietnam's first joint-stock commercial bank. Headquartered in Hanoi and listed on the Ho Chi Minh Stock Exchange under the ticker MSB, the bank serves nearly 10 million retail and nearly 100.000 corporate customers across the country.

SmartOSC

With a 20-year track record, SmartOSC is a leading digital transformation consultancy and implementation partner in Asia-Pacific, helping global enterprises elevate their digital experiences. Combining agile strategy with deep technical expertise, SmartOSC delivers end-to-end solutions across Digital Banking, Digital Commerce, Omnichannel, Data, and AI. Trusted by brands including CIMB, MSB, LG, Sony, PayPal, and OCB, SmartOSC helps businesses optimize operations, enhance customer experiences, and drive sustainable growth.

The issuer is solely responsible for the content of this announcement.

Hashtags: #Backbase

https://backbase.com

https://www.linkedin.com/company/backbase/

https://x.com/backbase

https://www.instagram.com/backbase_global/

*PU Prime has launched a redesigned trading app under its "A Clearer Way to Trade" campaign, creating a simpler and more intuitive experience for traders.

*The redesigned app brings Live Trading and Copy Trading closer together while giving users greater control over leverage and position management.

*An integrated Explore feature provides market news, analysis, and economic event insights directly within the trading app.

EBENE, Mauritius, Sept. 29, 2026 (GLOBE NEWSWIRE) -- PU Prime, a global multi-licensed online brokerage, has launched a redesigned trading app under its "A Clearer Way to Trade" campaign. Rather than simply adding more features to a single interface, the redesign reorganizes the app around the user's entire trading journey, delivering a clearer, more intuitive way to trade.

The launch builds on a platform that has already received industry recognition, including recent accolades at FX Expo Buenos Aires, iFX Expo Dubai, and the Global Forex Award in 2026, reflecting PU Prime's continued focus on improving the end-to-end trading experience.

A Simpler Copy Trading Experience

The redesigned app makes it easier for users to move between different trading activities without unnecessary steps. A consolidated trading interface simplifies account switching between Live Trading and Copy Trading accounts, and lets users browse and follow signal providers with just a few taps. By bringing these functions closer together, the updated experience helps reduce friction and makes Copy Trading more accessible within the wider PU Prime ecosystem.

Greater Control Over Risk Management

The redesigned app also gives users greater control over how they manage their trading exposure. Eligible users can adjust leverage directly when placing a trade, without contacting customer support, allowing them to manage account settings more conveniently from within the app.

Position management has also been streamlined with a "Close All" function, enabling users to close all open positions more efficiently when market conditions change rapidly. Together, these enhancements give traders more direct control over key account and position management functions.

Market News and Insights, Built In

The new Explore feature brings market information closer to the trading experience. Users can quickly review market movements, follow key developments, and prepare for upcoming economic events directly within the app. Curated market analysis from established sources also provides additional context to help users as they assess market opportunities.

By bringing research and execution into a single environment, the redesigned app reduces the need to switch between multiple platforms when following the markets.

Celebrating the Launch

To mark the launch of the redesigned app, PU Prime is introducing an in-app Lucky Draw Deposit Bonus promotion, running from September 29 to October 27, 2026. Eligible users can participate through the PU Prime App and explore the redesigned trading experience as part of the campaign.

The "A Clearer Way to Trade" campaign reflects PU Prime's commitment to making the digital trading experience simpler, more intuitive, and better connected without compromising the functionality expected by active traders. The redesigned PU Prime App pairs a fresh UI/UX with a more cohesive structure, bringing previously scattered functionalities together, so users spend less time navigating between screens and more time focused on their trading decisions.

About PU Prime

Founded in 2015, PU Prime is a leading global fintech company and trusted CFD broker. Today, it offers regulated financial products across forex, commodities, indices, shares, and bonds. Operating in over 100 countries with more than 40 million app downloads, PU Prime provides innovative trading platforms and an integrated copy trading feature, empowering traders worldwide to achieve financial success with confidence.

Copyright 2026 GlobeNewswire, Inc.

Collaboration broadens access to high-performance ingredients and accelerates formulation innovation

DOWNERS GROVE, Ill., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Univar Solutions USA LLC ("Univar Solutions" or "the Company"), through its Ingredients + Specialties (I+S) from Univar Solutions division, announced a new exclusive distribution partnership with the CABB Group.

CABB Group is a leading Contract Development and Manufacturing Organization (CDMO) and fine chemicals provider, specializing in customized active ingredients and high-purity solutions for life sciences, personal care, crop science, and specialty applications. The agreement expands distribution of glycolic acid beyond EMEA to the United States and Canada, including the key ingredient GLYCOS Clear 70.

"Our collaboration with the CABB Group marks an exciting step forward in expanding high-performance solutions for the beauty and personal care markets across North America," said Nick Powell, CEO, Ingredients + Specialties from Univar Solutions. "Together, we're bringing deep technical expertise and proven glycolic acid capabilities to help customers create more effective, multi-benefit products. Building on our existing relationship, we're also pleased to expand our partnership in EMEA to now include the United States and Canada."

Glycolic acid is commonly used in cosmetic and skin care products and valued for its exfoliating role in a variety of formulations. It is frequently used in products intended to help enhance overall skin appearance and texture related to skin tone and radiance. Incorporating glycolic acid into Univar Solutions' portfolio aligns with the Company's strategic plan to invest in areas of growth, enhance its ingredient offerings, and empower customers to create differentiated, high-performing products.

"Univar Solutions' reach and expertise in specialty ingredients makes them the right partner to broaden the availability of our glycolic acid technologies," said Tobias Schalow, CEO of the CABB Group. "This exclusive partnership brings our glycolic acid to customers across the United States and Canada, helping ensure robust supply and consistent performance. Produced using renewable electricity, it reflects our commitment to sustainability without compromise. Our focus is on providing dependable solutions for the personal care industry and beyond, supporting brands that demand excellence in every formulation."

"This partnership with the CABB Group reinforces our mission to help support customers with the specialty ingredients they need for product growth and brand development," said James Peterson, global senior vice president of Care for Univar Solutions. "Together, we can accelerate growth in critical beauty and personal care applications by expanding access to ingredients known for their adaptability and effectiveness. With our product and innovation capabilities, we're empowering customers to develop next generation formulations across key markets."

Explore glycolic acid solutions and the full portfolio of beauty and personal care products and services available through I+S from Univar Solutions.

About Univar Solutions

Univar Solutions is a leading global specialty chemical and ingredient distributor representing a premier portfolio from the world's leading producers. With one of the industry's largest private transportation fleets and technical sales force, unparalleled logistics know-how, deep market and regulatory knowledge, formulation and recipe development, and leading digital tools, the Company is well-positioned to offer tailored solutions and value-added services to a wide range of markets, industries, and applications. While fulfilling its purpose to help keep communities healthy, fed, clean, and safe, Univar Solutions is committed to helping customers and suppliers innovate and focus on Growing Together. Learn more at univarsolutions.com.

About Ingredients + Specialties from Univar Solutions

Ingredients + Specialties from Univar Solutions brings the best products, people, and results to specialty customers and suppliers seeking to power modern life. By combining science, innovation, and deep expertise with a leading specialty portfolio, we help find the solutions needed to safely improve lives and communities across the globe. Learn more at univarsolutions.com.

About CABB Group

CABB Group is a leading provider of contract manufacturing (CDMO) and fine chemicals, specializing in customized active ingredients and high-purity solutions for life science, personal care, crop science, and specialty applications. The CABB Group combines leading-edge technologies with a global largescale production network to deliver reliable, sustainable, and cost-efficient solutions to provide customized solutions for complex chemistries. CABB with around 1,000 employees, c. ?494 million revenue, and five production sites is a partner in fine chemistry turning complex chemistry into reliable and cost-efficient solutions. Learn more at cabb-chemicals.com

Forward-Looking Statements and Information

This communication contains "forward-looking statements" under applicable law regarding financial and operating items relating to the Company's business. Forward-looking statements generally can be identified by words such as "believes," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates," "anticipates" or other comparable terms. All forward-looking statements made in this communication are qualified by this cautionary language.

Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond the Company's control, that could result in expectations not being realized or could otherwise materially and adversely affect the Company's business, financial condition, results of operations or cash flows. Although the forward-looking statements are based on what management believes to be reasonable assumptions, we caution you that the forward-looking information presented in this communication is not a guarantee of future events or results, and that actual events or results may differ materially from those made in or suggested by the forward-looking information contained in this communication.

For additional information regarding factors that could affect the Company, please see the Company's most recent annual report and other financial reports, including the information set forth under the caption "Risk Factors." Any forward-looking statements represent the Company's views only as of the date of this communication and should not be relied upon as representing the Company's views as of any subsequent date, and the Company undertakes no obligation, other than as may be required by law, to update any forward-looking statement.

Copyright 2026 GlobeNewswire, Inc.

Source: De Beers Group

Reimagining A Diamond Is Forever for a New Era, Redefining Natural Diamond Storytelling

BEIJING, CHINA - Media OutReach Newswire - 29 September 2026 - De Beers Group unveils the campaign film for Desert diamonds. Following the Desert diamonds Asian launch in Shanghai on 29 July, the campaign extends across 25 key cities in China, timed to Jewellery & Gem WORLD Hong Kong (JGW) and the Golden Week. Blending classical Chinese poetry with contemporary aesthetics, the film reinterprets A Diamond Is Forever for a new era and places natural diamonds within a register of cultural resonance and inner narrative.

Desert diamonds are De Beers Group's contemporary expression of natural diamonds, honouring the rarity of each stone and the brilliance forged by nature under immense heat and pressure over billions of years. The category answers a younger generation's wish to resist definition by convention, to embrace the authentic self and to speak in its own voice. It carries natural diamonds beyond the bridal occasion into a lasting choice whether given to someone else or kept for oneself.

The soul of the campaign traces back to the landscape evoked by the Tang Dynasty poet Wang Wei in the lines: "In the great desert, a single smoke rises straight; over the long river, the setting sun is round." Through an exceptionally concise visual language, the film distils the rawness, vastness and stillness of the desert into the essence of its narrative, conveying to a younger generation the deeper core of Desert diamonds - authenticity, individuality and inner radiance.

Through the lens, "straight," "long" and "round" are no longer simply poetic images, but the truest forms of all things once every ornament has fallen away. In the desert, artifice is stripped away by wind and sand, leaving heaven and earth revealed in their purest geometric contours. This untouched, elemental state evokes an almost Zen-like sense of completeness. It is in such an extreme environment that natural diamonds take shape, and each refracted ray of light echoes the silent rhythm of the deep desert-brilliant and untamed.

Working in a minimalist visual language and an understated narrative, the film presents its four models in their most authentic state. Every frame is pared back to its essence, capturing the most unadorned dialogue between a person and a natural diamond. Throughout, the rhythm of the gong, a traditional Chinese instrument, provides a continuous thread. Its resonant Eastern tones answer the imagery of the desert, evoking a distinctive sense of freedom and ease.

L? Mo, Director, said: "Young people today move between tradition and modernity, with classical Chinese aesthetics and global culture coexisting in their inner world. At its core, Wang Wei's poetry embodies a distinctly Eastern form of minimalism - 'straight,' 'long' and 'round' reveal the original forms of all things once everything superfluous has been stripped away, reflecting an independent spirit that neither follows trends nor caters to popular taste.

This resonates with the younger generation's refusal to be defined by external expectations. Through this film, I hope to convey that your sharpness, your edges, and even all the 'imperfections' that others may never see are precisely the irreplaceable marks that make you who you are."

De Beers Group's consumer research places figures to this: 95% of Chinese respondents said they would like to own a Desert diamond, 94% agreed that Desert diamonds are distinctive, and 96% viewed them as an innovative departure from tradition. As authenticity and individuality increasingly shape contemporary values, the natural beauty of Desert diamonds-and the uniqueness found in their imperfections-speaks to the radiance of a generation unwilling to be tamed, whether the occasion is a personal milestone or a feeling for someone cherished that words cannot fully convey.

The campaign runs across 25 key cities, among them Beijing, Shanghai and Guangzhou, reaching audiences through digital television and social media platforms and through an integrated online and offline approach. De Beers Group continues to work with its three strategic retail partners-Chow Tai Fook, Chow Sang Sang and TSL | Tse Sui Luen-extending the campaign onto the jewellery floor, where the rich natural colours and distinctive character of Desert diamonds can be seen at close range.

Building on the spirit of A Diamond Is Forever, the new campaign film offers a contemporary reading of an idea now nearly 80 years old. Since its creation in 1947, the line has embodied the lasting, rare and timeless qualities of natural diamonds. Drawing on Chinese culture, the film opens a dialogue with a younger generation around the authentic self, taking the idea beyond traditional expressions of emotional commitment towards individuality, personal expression and inner radiance.

Shaped entirely by nature, Desert diamonds hold a radiance that comes from within. What lasts is not only the rarity of a natural diamond through the passage of time, but the strength to stay true to oneself and shine boldly. And what is carried forward is more than the value held in a stone: it is a spirit of authenticity and individuality that stays with a younger generation through the years.

For more information on natural diamonds, please follow and visit the official channels below:

De Beers Group official website www.debeersgroup.com

Natural Diamonds Instagram @ADiamondisForeverhk

Website: www.adiamondisforever.com/zh-hk

About De Beers Group

Established in 1888, De Beers Group is the world's leading diamond company, with unrivalled expertise in the exploration, mining, sales and marketing of diamonds. Together with its partners, De Beers Group employs more than 20,000 people across the diamond value chain.

It is the world's largest diamond producer by value, with mining operations in Botswana, Canada, Namibia and South Africa. Innovation sits at the heart of the Group's strategy, underpinning a portfolio of brands including De Beers London and Forevermark, as well as pioneering solutions such as Gem Fair and Tracr, its diamond mining and traceability programmes.

De Beers Group provides education and laboratory services through the De Beers Institute of Diamonds, and its Ignite team has introduced a range of technology systems for diamond sorting, detection and classification, delivering quality service and advanced technology to the diamond industry. De Beers Group is a member of Anglo American plc. For further information, visit www.debeersgroup.com.

About Building Forever

In 2020 De Beers Group established a set of sustainability goals to deliver a blueprint for lasting positive impact in the countries and regions where it operates and across the diamond value chain, so that every diamond it discovers and recovers brings enduring benefit to the people and environments of the places it comes from.

Building Forever sets out a comprehensive framework built on four pillars: leading ethical practices across the industry, partnering for thriving communities, protecting the natural world and accelerating equal opportunity - guiding the Group towards a fairer, safer, cleaner and healthier future in which communities prosper and the environment is protected.

De Beers Group works to raise industry standards, improve transparency of diamond provenance and improve conditions for artisanal miners. Across its operations, the Group follows best practice in biodiversity, water management, air quality, greenhouse gas emissions, waste management, and mine closure and rehabilitation.

De Beers Group also works with stakeholders to build a sustainable future and to raise living standards in the communities where it operates, particularly in health and wellbeing, education and skills development, economic diversification and livelihood support. The Group actively promotes inclusive economic development and welcomes diverse perspectives to help shape the future of its business, its communities and wider society.

It places particular emphasis on addressing the industry's long-standing gender imbalance and on encouraging a new and more diverse generation of talent into the diamond and jewellery industry.

The issuer is solely responsible for the content of this announcement.

Hashtags: #DeBeersGroup #ADiamondIsForever #NaturalDiamonds #Desertdiamonds #Diamonds

Frank Eagleton promoted to Managing Director, Asia Pacific, and Rehan Wickremeratne appointed Partnerships Lead as Aircall invites partners to collaborate on AI voice agents

SYDNEY, AUSTRALIA - Media OutReach Newswire - 29 September 2026 - Aircall, the AI-powered customer communications platform trusted by more than 24,000 businesses worldwide, today announced the next phase of its Asia Pacific strategy: building on an established base in Australia and New Zealand to expand across Southeast Asia.

With more than 24,000 customers worldwide, Aircall is strengthening its commitment to a region where demand is accelerating. It reflects a clear shift toward customer communications that combine intelligent voice agents, automated workflows and real-time coaching in a single platform.

Aircall is investing heavily in Asia, and localisation is central to that strategy. Integration with WhatsApp is one clear example of how that plays out in practice.

"Asia is a natural market for AI voice agents. The region spans dozens of languages and markets, each with its own customer expectations, and voice remains a primary way people reach the businesses they buy from," said Frank Eagleton, Managing Director, Asia Pacific, Aircall.

Regional appetite is strong: 87% of Asia Pacific CEOs expect a return on their AI investments within three years, according to KPMG. That confidence is meeting rapid change in customer service, where Gartner reports 85% of customer service leaders will explore or pilot customer-facing conversational generative AI in 2025.

According to Aircall, AI Voice Agent will help teams around APAC meet this always-on demand by handling routine, high-volume conversations at any hour and in local languages, while passing the interactions that call for judgement or empathy to a person.

To lead this next stage, Aircall's Frank Eagleton has stepped into the role of Managing Director, Asia Pacific. Eagleton will oversee the company's regional growth and market expansion through a channel-first approach, working alongside partners to reach and support customers across diverse Asian markets.

Aircall has also appointed Rehan Wickremeratne to lead the push, charging him with developing the partner ecosystem that will support it. "Southeast Asia is a dynamic and key growth region for us, and we're building our presence the same way we built ANZ: through partners who already have the trust of local businesses. Across these markets, that means being where customers already are"

"AI voice agents are changing what customer conversations can do. They're handling routine demand instantly while freeing teams to focus on the moments that need a human," said Eagleton. "That's the shift we're bringing to Asia, and it's a practical one: technology that does real work and takes tangible action. After huge success in Australia and New Zealand, expansion across Southeast Asia is the natural next step."

The benefits run both ways. For customers, AI voice agents mean faster resolutions, round-the-clock availability and conversations in their own language, without losing the human connection that builds trust. For channel partners, they open a clear opportunity: to localise, integrate and deliver AI voice agents as a service, building deeper, longer-term relationships with the businesses they serve. Aircall is inviting technology providers, resellers and service partners across the region to explore how they can work together to bring these capabilities to local markets.

"The most useful AI voice agents won't be built in isolation. They'll be shaped with partners who understand local markets, languages and customer expectations," said Wickremeratne. "We want to expand that ecosystem across Asia, and we would welcome conversations with partners who share that ambition."

About Aircall

Aircall is an AI-powered customer communications platform that brings together intelligent voice agents, automated workflows and real-time coaching in one intuitive platform. The platform helps more than 24,000 businesses collaboratively manage voice, SMS, and WhatsApp conversations, deliver real-time coaching and AI playbooks during live calls, handle high-volume inbound and outbound interactions autonomously through AI Virtual Agents, automate post-call workflows, and connect every interaction to the tools they already use across 250+ native integrations. Founded in Paris, Aircall has surpassed $200 million in ARR and serves customer-facing teams across more than 100 countries.

The issuer is solely responsible for the content of this announcement.

Hashtags: #Aircall

*DEGEVMA is now FDA-approved across all indications of the reference product, Xgeva (denosumab), to help prevent bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy.

*FDA approval of DEGEVMA marks another milestone in Teva's Pivot to Growth strategy, demonstrating our ability to bring high-quality, more affordable treatment options to patients across complex therapeutic categories.

*DEGEVMA is Teva's second FDA-approved biosimilar in 2026 and, together with PONLIMSI (denosumab-adet), establishes Teva's comprehensive denosumab biosimilar portfolio across the indications of the reference products Xgeva and Prolia (denosumab).

TEL AVIV, Israel, and PARSIPPANY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVMA (denosumab-adet) as a biosimilar to Xgeva (denosumab).

DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy.

The FDA approval of DEGEVMA, together with PONLIMSI (denosumab-adet), which was approved by the FDA in March 2026, establishes a comprehensive U.S. denosumab biosimilar portfolio spanning the indications of both Xgeva and Prolia (denosumab), respectively. Now, healthcare professionals and patients are able to gain expanded access to biologic treatment options in oncology-related bone disease and osteoporosis care.

"Our R&D mission is grounded in a clear commitment: translating complex biologic science into high-quality treatment options that address patient needs," said Rob Cook, Head of Global Technical Development & Generics R&D at Teva. "The approval of DEGEVMA reflects the scientific, clinical and regulatory expertise behind our in-house biosimilars capabilities and our continued focus on expanding access to important biologic medicines."

Biologics like denosumab represent a significant portion of healthcare expenditures, particularly in oncology. The introduction of biosimilars is critical to driving down systemic healthcare costs while broadening patient access to complex, life-enhancing medications.

"The last thing a person living with a cancer diagnosis or their families should have to worry about is access to their medicine," said Thomas Rainey, Senior Vice President, U.S. Biosimilars at Teva. "The approval of DEGEVMA is a powerful example of Teva's Pivot to Growth strategy in action because it represents an important step in expanding treatment options for patients and supporting healthcare systems with a high-quality biosimilar."

The FDA approval of DEGEVMA was based on a totality of evidence, including analytical and clinical data demonstrating similar efficacy, safety and immunogenicity profile as the reference product, Xgeva. DEGEVMA is a human monoclonal antibody that binds to the RANKL protein, an essential regulator of osteoclast formation, function and survival.

By inhibiting RANKL, DEGEVMA decreases bone resorption and cancer-induced bone destruction. The comprehensive data package submitted to the FDA demonstrated that DEGEVMA has no clinically meaningful differences from the reference product in terms of safety, purity and potency.

Teva anticipates launching DEGEVMA and PONLIMSI in the U.S. in the coming months, aligning with its broader biosimilar commercialization strategy.

DEGEVMA is currently approved in the European Union (EU). Learn more about Teva's global biosimilars portfolio and commercialization capabilities at www.tevabiosimilars.com.

Use of Trademarks

Xgeva and Prolia are registered trademarks of Amgen, Inc.

About DEGEVMA

DEGEVMA (denosumab) is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy.

The active substance, denosumab, is a human monoclonal IgG2 antibody that targets the protein RANKL, essential for the formation, function, and survival of osteoclasts-the cells responsible for bone resorption. By binding to RANKL with high affinity and specificity, denosumab prevents the interaction between RANKL and RANK, leading to a decrease in bone resorption in cortical and trabecular bone.

DEGEVMA will be available as a 120mg/1.7mL solution for injection in a vial.

DEGEVMA is a biosimilar medicinal product, similar to the reference product Xgeva (denosumab), which was approved in the EU on November 18, 2025.

Comprehensive analytical, preclinical, and clinical data demonstrate that DEGEVMA has comparable quality, safety and efficacy to the reference product.

INDICATIONS

DEGEVMA is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.

DEGEVMA is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

DEGEVMA is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Pre-existing hypocalcemia must be corrected prior to initiating therapy with DEGEVMA.

DEGEVMA is contraindicated in patients with known clinically significant hypersensitivity to DEGEVMA or denosumab products.

WARNINGS AND PRECAUTIONS

Drug Products with Same Active Ingredient

Patients receiving DEGEVMA should not receive other denosumab products.

Hypersensitivity

Clinically significant hypersensitivity including anaphylaxis has been reported with use of DEGEVMA. Reactions may include hypotension, dyspnea, upper airway edema, lip swelling, rash, pruritus, and urticaria. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue DEGEVMA therapy permanently.

Hypocalcemia

DEGEVMA can cause severe symptomatic hypocalcemia, and fatal cases have been reported. Correct pre-existing hypocalcemia prior to DEGEVMA treatment. Monitor calcium levels, throughout DEGEVMA therapy, especially in the first weeks of initiating therapy, and administer calcium, magnesium, and vitamin D as necessary. Concomitant use of calcimimetics and other drugs that can lower calcium levels may worsen hypocalcemia risk and serum calcium should be closely monitored. Advise patients to contact a healthcare provider for symptoms of hypocalcemia. Do not take DEGEVMA if you are allergic to denosumab or any of the ingredients of DEGEVMA.

An increased risk of hypocalcemia has been observed in clinical trials of patients with increasing renal dysfunction, most commonly with severe dysfunction (creatinine clearance less than 30 mL/min and/or on dialysis), and with inadequate/no calcium supplementation. Monitor calcium levels and calcium and vitamin D intake.

Osteonecrosis of the Jaw (ONJ)

Osteonecrosis of the jaw (ONJ) has been reported in patients receiving DEGEVMA, manifesting as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration, or gingival erosion. Persistent pain or slow healing of the mouth or jaw after dental surgery may also be manifestations of ONJ.

In clinical trials in patients with cancer, the incidence of ONJ was higher with longer duration of exposure. Patients with a history of tooth extraction, poor oral hygiene, or use of a dental appliance are at a higher risk of developing ONJ. Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections.

Perform an oral examination and appropriate preventive dentistry prior to the initiation of DEGEVMA and periodically during DEGEVMA therapy. Advise patients regarding oral hygiene practices. Avoid invasive dental procedures during treatment with DEGEVMA. Consider temporary discontinuation of DEGEVMA therapy if an invasive dental procedure must be performed.

Patients who are suspected of having or who develop ONJ while on DEGEVMA should receive care by a dentist or an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.

Atypical Subtrochanteric and Diaphyseal Femoral Fracture

Atypical femoral fracture has been reported with DEGEVMA. These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or short oblique in orientation without evidence of comminution.

Atypical femoral fractures most commonly occur with minimal or no trauma to the affected area. They may be bilateral, and many patients report prodromal pain in the affected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs. A number of reports note that patients were also receiving treatment with glucocorticoids (e.g., prednisone) at the time of fracture.

During DEGEVMA treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Any patient who presents with thigh or groin pain should be suspected of having an atypical fracture and should be evaluated to rule out an incomplete femur fracture. Patients presenting with an atypical femur fracture should also be assessed for symptoms and signs of fracture in the contralateral limb. Interruption of DEGEVMA therapy should be considered, pending a risk/benefit assessment, on an individual basis.

Hypercalcemia Following Treatment Discontinuation in Patients with Giant Cell Tumor of Bone and in Patients with Growing Skeletons

Clinically significant hypercalcemia requiring hospitalization and complicated by acute renal injury has been reported in DEGEVMA-treated patients with giant cell tumor of bone and patients with growing skeletons. Within the first year after treatment discontinuation, monitor patients for signs and symptoms of hypercalcemia and treat appropriately.

Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation

Multiple vertebral fractures (MVF) have been reported following discontinuation of treatment with denosumab products. Patients at higher risk for MVF include those with risk factors for or a history of osteoporosis or prior fractures.

When DEGEVMA treatment is discontinued, evaluate the individual patient's risk for vertebral fractures.

Embryo-Fetal Toxicity

Based on data from animal studies and its mechanism of action, denosumab products can cause fetal harm when administered to a pregnant woman.

Advise pregnant women and females of reproductive potential that exposure to DEGEVMA during pregnancy or within 5 months prior to conception can result in fetal harm.

ADVERSE REACTIONS

The most common adverse reactions in patients with bone metastases from solid tumors taking DEGEVMA were fatigue/asthenia, hypophosphatemia, and nausea. The most common serious side effect was dyspnea.

In patients with multiple myeloma, the most common adverse reactions were diarrhea, nausea, anemia, back pain, thrombocytopenia, peripheral edema, hypocalcemia, upper respiratory tract infection, rash, and headache. The most common serious side effect of DEGEVMA was osteonecrosis of the jaw.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Teva Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "may," "project," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance.

Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully commercialize DEGEVMA (denosumab-adet) a Biosimilar to Xgeva (denosumab) for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone, and for the treatment of hypercalcemia of malignancy, and PONLIMSI (denosumab-adet); our ability to successfully compete in the marketplace including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the section captioned "Risk Factors" and "Forward-looking Statements."

Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Teva Media Inquiries:  TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor Relations Inquiries:  TevaIR@Tevapharm.com

Copyright 2026 GlobeNewswire, Inc.

Hong Kong makes its debut at Monaco Yacht Show.

HONG KONG, Sept. 28, 2026 (GLOBE NEWSWIRE) -- The Hong Kong Tourism Board (HKTB) and Informa Markets marked a significant milestone in their three-year Strategic City Partnership with Hong Kong through a high-profile presence at the Monaco Yacht Show from 23 to 26 September, widely recognised as the world's leading superyacht exhibition.

The participation underscores Hong Kong's ambition to strengthen its position as Asia's premier hub for yacht tourism, marine leisure and luxury business events, while introducing international industry leaders to the inaugural Festival of Connoisseurs (TFOC), a new flagship luxury lifestyle and business platform set to debut in Hong Kong this November.

As the first stop of a global promotional roadshow under the partnership, the Monaco Yacht Show provided a valuable platform to engage yacht owners, marine industry leaders, luxury brands, investors and high-net-worth travellers from around the world. The initiative reflects Hong Kong's growing role as a gateway connecting international businesses with opportunities across the Chinese Mainland and the wider Asian market.

Under Informa Markets' Strategic City Partnership with Hong Kong, HKTB will participate in a series of globally renowned luxury and lifestyle exhibitions, including the Monaco Yacht Show, Palm Beach International Boat Show, Basilia Jewellery & Watch Fair, Top Marques Monaco and the Fort Lauderdale International Boat Show. The partnership aims to elevate Hong Kong's international profile among the global luxury, marine and lifestyle sectors while supporting the development of TFOC into one of Asia's leading luxury business and lifestyle platforms.

At the Monaco Yacht Show, HKTB joined forces with the Hong Kong Economic and Trade Office, Brussels, Airport Authority Hong Kong and AsiaWorld-Expo to form the Hong Kong delegation, showcasing the city's combined strengths in tourism, aviation, business events and international trade.

Mr. Anthony Lau, HKTB Executive Director, said: " The Monaco Yacht Show brings together the world's most influential players in the yachting industry and provides an ideal platform for Hong Kong to tell its story to a highly valuable international audience. Beyond being a world-class destination, Hong Kong serves as a super-connector and super value-adder, uniquely linking global businesses, investors and brands with opportunities across the Greater Bay Area, the Chinese Mainland and Asia.

With a vibrant marine ecosystem, world-class infrastructure and a growing portfolio of international marine and sailing events, Hong Kong is well positioned to become a leading hub for yacht tourism and marine business in Asia. Through our partnership with Informa Markets and the launch of TFOC, we aim to create new opportunities for luxury tourism, business exchange and investment in the region."

Informa Markets sees strong potential in Hong Kong for launching and growing new flagship experiences in the region. Hong Kong offers a compelling proposition for the global yachting and marine industry. Home to one of the world's finest natural harbours and supported by extensive international air connectivity, the city provides direct access to the rapidly expanding wealth markets of the Greater Bay Area and Asia.

Recent initiatives to streamline yacht entry procedures, alongside ongoing marina developments and investments in marine infrastructure, are creating new opportunities for yacht owners, operators and marine-related businesses seeking to establish a presence in the region.

The city's growing calendar of international marine and sailing events, including SailGP and the Dragon World Championship, further enhances its appeal as a year-round destination for marine tourism, business networking and premium lifestyle experiences.

Looking ahead, Hong Kong will host the inaugural TFOC from 4 to 6 November 2026 at AsiaWorld-Expo. Embracing an innovative "city-as-your-showroom" concept, the event will extend beyond a traditional exhibition venue, transforming iconic locations across Hong Kong into immersive showcases for luxury and lifestyle experiences.

Over three days, participants will explore nine curated themes spanning yachting, mobility, art, travel, wellness, gastronomy and beyond. Making its debut in Hong Kong this year, TFOC is set to evolve into a citywide flagship festival from 2027, further highlighting Hong Kong's unique position as the world's meeting place where global business, culture and premium lifestyle converge.

About Hong Kong Tourism Board

The Hong Kong Tourism Board (HKTB) is a Government-subvented body. Operating 15 offices around the world and representative offices in seven different markets, its primary mission is to maximise the social and economic contribution that tourism makes to the community of Hong Kong, and consolidate the city's position as a world-class destination.

The HKTB works closely with the Government, travel industry and other partners to promote Hong Kong worldwide, widen the range of tourism products and elevate service standards, as well as enhance the experiences of visitors during their stay.

About The Festival of Connoisseurs

The Festival of Connoisseurs (TFOC) is Asia's premier luxury lifestyle show platform, debuting its soft launch in Hong Kong in November 2026. Organised by Informa Markets and supported by the Hong Kong Tourism Board and other strategic partners, the Festival showcases dynamic worlds of connoisseurship - including Marina, Marque, Vault, Galerie, Passage, Estate, Zenith, Vitalis, Culinaire and more - across Hong Kong's iconic venues and destinations. "Where the World's Finest Converge in Asia's Most Dynamic City." For more information, please visit https://www.tfochk.com/   

   

Copyright 2026 GlobeNewswire, Inc.

MONACO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Sustainability is increasingly becoming a defining element of the modern marina. But for M3 Monaco, a consultancy specialized in the development and management of marinas, yacht clubs and nautical centers, it is not simply about adopting individual green technologies or reducing environmental impact.

It requires a broader approach combining infrastructure, operations, management, environmental performance and the overall quality of the destination.

 This is the philosophy behind the Monaco Smart & Sustainable Standard (S3), a certification program designed to assess and support marinas, yacht clubs and nautical centers in their transition towards higher standards of sustainability and operational excellence.

As Jose Marco Casellini, CEO of M3 Monaco, explains, the S3 Label is designed as a structured assessment rather than simply a sustainability badge. "We come, we assess a project, and we verify if this project follows all the criteria coming from sustainability, environment, methodology, operational skills as well, and procedure."

The process is structured in three phases: diagnostic and application, validation and optimization, including an on-site assessment and action plan, and award and community, which recognizes the standard achieved while encouraging knowledge sharing and continuous improvement.

The latest recognitions highlight different approaches to these principles. The destinations awarded in Monaco illustrate how principles can be integrated on four levels: Horizon, Regatta, Flagship and Sovereign. The Yacht Club de Monaco, founded in 1953 and chaired by HSH Prince Albert II since 1984, was recognized for combining yachting excellence, education, innovation and environmental responsibility, including through the SEA Index.

Jeddah Yacht Club & Marina was recognized for combining hospitality with community engagement and marine protection, including sailing programs for children and sea turtle conservation, while Port de Saint-Florent in Corsica was recognized for its long-term vision and leadership in raising marina standards.

For Amaala Yacht Club, the 119-berth marina on Saudi Arabia's Red Sea coast, the certification provides an external benchmark for a new destination. "I believe it's important because it's a good benchmark and it shows the community that you're serious about what you're doing," said General Manager Adrian Peet.

A similar perspective comes from Ayla Marina in Aqaba, Jordan, part of a wider mixed-use development. "Our participation shows our commitment to these things which are the core values in this business," said Ayla Marina manager Adel Maani.

The S3 Label is therefore not presented as the end of the process, but as part of a continuous journey, providing marinas with a framework to measure performance, identify areas for improvement and work towards more sustainable and higher-performing destinations.

For more information:

Press Office LaPresse - ufficio.stampa@lapresse.it

Copyright 2026 GlobeNewswire, Inc.

Source: Alibaba Group

Alibaba to become Nets' Official Jersey Patch Partner, and bring Real-Time 360? Replay and personalized fan collectibles to Barclays Center

NEW YORK, UNITED STATES - Media OutReach Newswire - 28 September 2026 - Alibaba Group and Brooklyn Sports & Entertainment today announced a strategic multi-year partnership naming Alibaba an Official Technology and Cloud Partner of the Brooklyn Nets.

The partnership pairs Alibaba's cloud technology with the Brooklyn Nets' live game replay, in-game entertainment and marketing initiatives, creating more immersive experiences for fans in the arena.

As the Nets' Official Jersey Patch Partner, Alibaba will support the team's 60th anniversary season-a year-long campaign honoring iconic players, defining moments and milestones across the franchise's history-through technology-enabled fan experiences and marketing activations.

"Alibaba has long partnered with leading sports organizations worldwide, giving us a deep understanding of how to deliver technology at the scale and speed live sports demand," said Toby Xu, Chief Financial Officer, Alibaba Group. "We are excited to team up with the Brooklyn Nets to unlock new possibilities in sports innovation. As we head into the new season, we look forward to delivering immersive experiences for fans at Barclays Center and beyond."

"The Brooklyn Nets are committed to investing in technology to enhance the fan experience and elevate how basketball is experienced at Barclays Center," said Sam Zussman, CEO, Brooklyn Sports & Entertainment. "As we celebrate 60 seasons of Nets basketball, we are intentional about how we innovate across our marketing and in-arena experiences, and this partnership with Alibaba will help us develop new ways to connect fans with our history and identity."

Beginning with the 2026-27 NBA season, Alibaba's technology will power a Real-Time 360 Replay system at Barclays Center, bringing faster and more innovative replays. Through the in-arena "Nets Figure Lab," fans will also be able to create personalized collectible cards using Alibaba's technology.

Across the season, Alibaba and the Nets will use the partnership to test and scale innovative technology and marketing applications on and beyond game day, enhancing fan experiences while supporting the next chapter of Nets basketball. For the Nets, the collaboration represents an investment in the future of the franchise, using technology and creative collaboration to honor six decades of history while building what comes next.

The issuer is solely responsible for the content of this announcement.

Hashtags: #AlibabaGroup

*New Software Defined MV architecture delivers up to 3x faster ordering and manufacturing, up to 2x faster commissioning, zero-downtime upgrades, and a simplified footprint with less wiring and fewer components

*Architecture piloted with Equinix in a live colocation data center environment

LAS VEGAS, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Schneider Electric, a global energy technology leader, today unveiled the world's first fully Software-Defined Medium Voltage (MV) switchgear, redefining how electrical distribution systems are designed, deployed, and operated.

Announced at YOTTA 2026 (September 28-30, Las Vegas), the innovation is part of Schneider Electric's broader vision for Software Defined Energy, which decouples system intelligence from hardware to create more flexible, resilient, and sustainable energy infrastructure. As electrification accelerates and AI factories drive data center demand, this approach allows power infrastructure to evolve at the same pace as the digital services it supports. It marks the next step for Schneider Electric as the energy technology partner for the organizations that run critical operations.

Traditional Medium Voltage systems rely on engineered-to-order, custom-built designs, resulting in longer lead times, complex procurement processes, and limited scalability. Software Defined MV Equipment addresses these constraints by shifting functionality into software and enabling over-the-air updates that deliver new features and performance improvements without physical modifications. Standardized hardware platforms replace bespoke designs, making systems easier to deploy, adapt, and scale. Importantly, upgrades can be implemented with zero operational downtime, ensuring uninterrupted service.

This transformation is supported by a simplified and modular hardware architecture that significantly reduces system complexity. By moving away from fully custom assemblies toward configurable, software-enabled modules, Schneider Electric enables faster ordering and manufacturing while lowering the environmental impact of production. Based on Schneider Electric studies and estimations, this approach delivers up to 3? faster ordering and manufacturing, and a simplified footprint with less wiring and fewer components. At the same time, digital-first commissioning processes, supported by automated testing and intuitive interfaces, accelerate deployment and simplify on-site operations, enabling up to 2? faster commissioning and onsite acceptance testing.

Beyond deployment, Software Defined MV Equipment embeds energy intelligence across the system lifecycle. With built-in connectivity and analytics, customers benefit from real-time visibility into system performance, as well as AI-powered predictive maintenance through EcoCare Services - turning real-time data into foresight, not hindsight, while reducing unplanned downtime and improving operational efficiency.

"Data centers are being asked to build faster than traditional power infrastructure can move," said Melton Chang, Executive Vice President, Power Systems Division, Schneider Electric. "With Software Defined MV switchgear, we are bringing the logic of software to medium voltage equipment - so customers can deploy in a fraction of the time, standardize across regions, and add new capabilities with zero downtime. As their energy technology partner, we are making power infrastructure as agile as the digital operations it serves."

Schneider Electric's next-generation Software Defined MV Equipment is already deployed in the field through a pilot with Equinix, conducted in a live colocation data center environment.

"Software Defined MV Equipment transform the way we design, procure, build, and operate MV switchgear, allowing increased standardization for multiple use cases whilst maintaining the highest standards of safety, quality and reliability," said Greg Metcalf, Senior Director, Global Data Center Design and Innovation at Equinix. "We look forward to deepening our collaboration with Schneider Electric as we continue to innovate and scale for the future."

Building on this foundation, Schneider Electric will extend the Software Defined MV architecture across its medium voltage portfolio and, progressively, the rest of the powertrain - including PremSet and the AirSeT range (GM AirSeT, RM AirSeT, and SM AirSeT?). Pilot programs continue through 2027, with broader availability to follow in 2028.

Software Defined MV Equipment represents a shift toward a more dynamic and future-ready model of electrical infrastructure. It enables faster project execution, greater operational insight, and a transition from traditional capital-intensive deployments to lifecycle-driven service models. The result is a simpler, smarter, and more sustainable power ecosystem.

To learn more about Software Defined MV Equipment and register for product and availability updates, visit the web or download the white paper.

Press contact: mediarelations@se.com

About Schneider Electric

Schneider Electric is a global energy technology leader, driving efficiency and sustainability by electrifying, automating, and digitalizing industries, businesses, and homes. Its technologies enable buildings, data centers, factories, infrastructure, and grids to operate as open, interconnected ecosystems, enhancing performance, resilience, and sustainability.

The portfolio includes intelligent devices, software-defined architectures, AI-powered systems, digital services, and expert advisory. With 160,000 employees and 1 million partners in over 100 countries, Schneider Electric is consistently ranked among the world's most sustainable companies. 

Copyright 2026 GlobeNewswire, Inc.

Issuer: Vitals

HONG KONG SAR - Media OutReach Newswire - 28 September 2026 - Vitals today announced that it is extending its data-driven wellness model to Singapore and Hong Kong. The move expands a platform built around testing, interpretation, telehealth and recurring products into additional Asian markets.

Vitals is a diagnostics-led health and wellness platform founded and led by Charles Temple, a New Zealand entrepreneur with more than 18 years of operating experience in Hong Kong and Southeast Asia. Its proposition is straightforward: rather than asking consumers to guess which vitamins, supplements or lifestyle changes they need, test first, interpret the results properly and build the recommendation around the individual.

The entry point is testing, and Vitals has made it deliberately easy. Its Comprehensive Wellness Test is non-invasive: a small hair sample collected at home is analyzed using German technology to screen more than 700 biomarkers spanning nutritional, metabolic and systemic indicators.

For customers who want clinical-grade data, Vitals Longevity blood programs - Essential Wellness, Advanced Vitality and Executive Longevity - cover up to 82 laboratory indicators, with a licensed nurse drawing the sample at the customer's home or office. Samples are processed by partner laboratories certified to ISO 15189 and by the Ministry of Public Health, and customers can add individual tests to any program.

Results are delivered digitally through the Vitals platform, where an AI analysis layer, working with the laboratory and the company's clinical team, turns raw values into a personalized report and a recommended protocol. Vitals is rolling out online consultations with licensed doctors for interpreting blood results, general health questions and, over time, physician-supervised programs, so that the customer does not have to bridge the gap between data and decision alone.

"Thailand offers a useful case study in how traditional consumer categories can be rebuilt around data," said Bruce Rockowitz, spokesperson for Vitals. The Vitals model connects testing, interpretation, medical advice, recommendations and recurring products into a single digital relationship.

Thailand already has many of the ingredients required for a wellness economy: a sophisticated healthcare sector, accredited laboratories, a strong tourism industry, established hospitality infrastructure and consumers increasingly familiar with premium health and beauty products. The personalized testing and supplements market in Thailand is forecast to grow from about $80 million in 2026 to $124 million by 2033, according to Grand View Research.

Vitals extends its data-driven wellness model across Asia

Vitals' own-brand supplement range is developed using the company's formulations, produced by third-party manufacturers in Thailand and independently tested. It sits alongside more than 100 global and local brands sold through Vitals' retail stores and online platform. Because every recommendation traces back to the customer's own results, the company can stay in contact to retest, refine the protocol and refill rather than relying on one-off purchases.

Vitals is now extending its model to Singapore and Hong Kong. The same logic can extend beyond supplements into hospitality, food, beauty, travel and healthcare, where adding data, personalization and digital distribution can potentially turn traditionally service-based businesses into recurring consumer platforms.

For more information about Vitals, visit: https://vitals.co.th/en

Hashtag: #Vitals

About Vitals

Vitals is a diagnostics-led health and wellness platform with physical stores and an online platform. It offers non-invasive hair-based wellness testing of more than 700 biomarkers, at-home blood testing with licensed nurse collection and certified laboratory analysis, AI-generated personalised reports and protocols, online consultations with licensed doctors, and a supplement marketplace combining its own third-party-tested range with more than 100 global and local brands.

Media Contact

Vitals

Media enquiries: info@vitals.co.th

Website: https://vitals.co.th/en

The issuer is solely responsible for the content of this announcement.

As the country's first renewable-powered Sovereign AI infrastructure, this strategic collaboration aims to foster local innovation and boost the national economy.

SINGAPORE - Media OutReach Newswire - 28 September 2026 - YCO Cloud is proud to announce its collaboration with Aolani and NVIDIA to deliver one of the first NVIDIA GB300 NVL72 cluster deployments in the Philippines.

This collaboration marks a significant milestone, bringing purpose-built sovereign AI infrastructure to the country for the first time.

Designed and implemented to meet global sustainability standards for water usage and dedicated renewable energy sources, the project aims to accelerate and solidify the country's ambitions in sovereign digital capabilities and forward-looking innovation.

Aolani provides AI infrastructure, GPU financing, deployment and operating capabilities; while YCO delivers purpose-built, sustainable and scalable digital infrastructure and local expertise.

By leveraging the combined strengths of YCO Cloud, Aolani, and NVIDIA, this initiative sets the foundation for a scalable, world-class AI ecosystem - accelerating local innovation while driving national economic productivity.

Scheduled for launch in the first quarter of 2027, the initial phase will deploy more than 10,000 NVIDIA Blackwell Ultra GPUs, extending state-of-the-art AI computing infrastructure to local government bodies, domestic enterprise, and local startups, while also attracting innovative global AI native companies.

As part of its commitment to environmental stewardship, YCO Cloud adheres to best practices to meet global standards for energy, water efficiency and environmental sustainability.

"The Philippines is now ready to scale on digital infrastructure with its robust submarine cable systems and growing renewable energy sources. To deliver a product that hasn't been built in the Philippines, we partnered with Science Park of the Philippines Inc. (SPPI), the pioneer and one of the largest industrial park developers in the country, with best-in-country power, water and connectivity infrastructure aligned with our sustainability goals.Our partnerships with Aolani and SPPI complement YCO Cloud's commitment to deliver green digital infrastructure to contribute to the next wave of growth in the country." said Nik de Ynchausti, CEO of YCO Cloud.

Nicholas Chia, CEO at Aolani, said, "As the leading neocloud in Asia, Aolani is committed to delivering high-performance and compliant AI infrastructure at speed and scale to support our customers operating at the forefront of AI innovation. Southeast Asia is fast becoming a key linchpin for global AI infrastructure, and the Philippines is emerging as a dynamic new market for digital infrastructure growth.

This collaboration will play a pivotal role in democratising access to advanced AI infrastructure in the Philippines, supporting the growth of the country's digital economy and AI ecosystem. We are excited to partner with YCO Cloud on this ambitious development to boost infrastructure growth and innovation."

The Philippine government welcomed the news of the partnership. "AI presents significant opportunities for innovation, job creation, and economic growth for the Philippines and Filipinos. We welcome the efforts of homegrown companies like YCO and its Singaporean partner, Aolani.

Anchored on their belief on the country's potential, we appreciate the commitment of both companies to work towards enabling Filipinos to become not just users but also builders and developers of AI. These forward-looking collaborations are key in shaping the Philippines' future and allow us to achieve purposeful progress together," said Leandro Angelo Y. Aguirre, Undersecretary of Department of Information and Communications Technology.

Rosemarie Edillon, Undersecretary of Department of Economy, Planning, and Development, said, "We thank YCO and Aolani for entrusting the Philippines with this significant role in AI infrastructure development. As we enter the Fifth Industrial Revolution, the Philippine Government stands ready to be an active partner in building a trusted, inclusive and ethical AI ecosystem for the Philippines and the world."

YCO Cloud

YCO Cloud's purpose and mission is to deliver sustainable mission-infrastructure designed to drive the Philippines forward. For more information, visit https://www.ycocloud.com/ and follow on YCO Cloud on LinkedIn.

Media Contact

H/Advisors on behalf of Aolani

pr@aolani.com

About Aolani

Where AI gets built in Asia. Founded in 2023, Aolani's AI factories enable enterprises, AI natives, and sovereigns to build with confidence, scale ambitiously, and move at hyper-speed in the world's fastest-growing AI market. Founded in Singapore and backed by compliant and purpose-built neocloud infrastructure, Aolani delivers the performance capabilities for next-generation AI. For more information, visit www.aolani.com and follow @AolaniCloud on LinkedIn.

The issuer is solely responsible for the content of this announcement.

Hashtags: #Aolani

Industry veteran brings more than two decades of oncology drug discovery leadership to advance Callio's dual-payload ADC pipeline

SAN DIEGO and SEATTLE and SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics ("Callio" or "the Company"), a global, clinical-stage biotechnology company advancing dual-payload antibody-drug conjugates (ADCs) as the next frontier of rationally designed targeted cancer therapy, today announced the appointment of Chris Hassig, PhD, as Chief Scientific Officer (CSO).

Hassig will lead Callio's research and discovery organization, overseeing the advancement of the Company's dual-payload ADC platform and pipeline.

Hassig joins Callio from Boundless Bio, where he served as CSO, building the company's drug discovery organization from its inception through advancement of three internally discovered first-in-class molecules into clinical development. Prior to Boundless Bio, he was CSO of Sierra Oncology (acquired by GSK) and Vice President of Drug Discovery at Sanford Burnham Prebys Medical Discovery Institute. He previously held drug discovery and research roles at Kalypsys, Inc. and the Scripps Research Institute.

"Chris is a highly accomplished oncology drug discovery leader, and I had the privilege of seeing that firsthand," said Zachary Hornby, Chief Executive Officer of Callio Therapeutics. "Over seven years together at Boundless Bio, Chris helped build a discovery engine that took novel biology from concept to clinic. Callio's dual-payload ADC platform is at a similar inflection point, and Chris's experience translating cutting-edge science into differentiated therapeutics makes him the right leader to help us realize our technology's full potential for patients with cancer."

"Callio is pursuing one of the most compelling unmet needs in oncology drug development today by designing ADCs to overcome resistance mechanisms that limit current therapies," said Hassig. "The team has already advanced CLIO-8221 into the clinic and built an ADC platform that systematically tests rationally designed dual-payload combinations for ADCs, optimized for specific tumor targets. I look forward to working with the innovative and talented Callio team to help build and advance a pipeline that can change outcomes for patients who currently have limited options."

Hassig earned a BA in Chemistry and Biochemistry from the University of California, San Diego, and a PhD in Molecular and Cellular Biology from Harvard University. He completed a postdoctoral fellowship at the University of California, Berkeley.

About Callio Therapeutics

Callio Therapeutics is a clinical-stage biotechnology company that is developing dual-payload antibody-drug conjugates (ADCs) as the next frontier of targeted cancer therapy to address high incidence tumors where better therapies are needed. Its proprietary platform pairs modular, adaptable linker technology with rationally selected synergistic payload combinations designed to block key resistance mechanisms that enable cancer's escape.

The Company's lead clinical program, CLIO-8221, is a HER2-targeted dual-payload ADC with potential to prevent and overcome treatment resistance that limits efficacy of current ADCs. Located in San Diego, Seattle, and Singapore, backed by top life science investors, and led by an experienced team with a track record of ADC development and oncology drug approvals, Callio Therapeutics is built to deliver the next generation of dual-payload ADCs and better outcomes for people living with cancer. For more information, visit www.calliotx.com and follow Callio Therapeutics on LinkedIn.

About CLIO-8221

HER2 is a clinically validated target for antibody-drug conjugates (ADCs), with multiple approved therapies demonstrating clinical benefit across tumor types. However, most patients eventually progress on treatment despite their tumors retaining HER2 expression. Mechanistic resistance to cytotoxic payloads has emerged as a key driver of treatment failure. CLIO-8221 is a novel, first-in-class, dual-payload ADC targeting HER2, designed to overcome emergent resistance.

CLIO-8221 delivers two mechanistically complementary payloads, a topoisomerase 1 (Topo1) inhibitor and an ATR inhibitor, directly to HER2-expressing tumors. While Topo1 inhibitors have shown strong clinical activity, activation of the DNA damage response following Topo1 inhibitor-induced replication stress represents a potential major driver of resistance.

By simultaneously inhibiting Topo1 and blocking the DNA damage response through ATR inhibition, CLIO-8221 is engineered to overcome payload insensitivity and further sensitize tumors to Topo1 inhibition. Developed using proprietary linker and ADC platform technologies, CLIO-8221 aims to maximize anti-tumor activity while reducing systemic toxicity, offering the potential for deeper and more durable responses in patients with HER2-expressing tumors.

CLIO-8221 is currently being evaluated in an ongoing Phase 1/2, first-in-human, dose-escalation and expansion study in adult patients with metastatic or unresectable HER2-expressing solid tumors, including those who previously received trastuzumab deruxtecan (T-DXd). The first patient was dosed in March 2026, and enrollment is ongoing in Australia and the US, with plans to open the study in China (NCT07300943).

Copyright 2026 GlobeNewswire, Inc.

FREMONT, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Following the September 16, 2026 joint report by Bain & Company, DBS Bank, and Vriens & Partners forecasting 4.8% annual regional growth while noting that tech scale-ups face widening institutional hurdles to capture foreign capital, Dmitry Shubov Consulting has issued a cross-border commercial advisory to guide Southeast Asian technology companies through corporate restructuring and regulatory compliance for U.S. market entry.

The report, From Tailwinds to Trade-Offs: Southeast Asia Outlook 2026-2035, notes that regional firms must establish institutional credibility to attract international capital. To address this structural gap, Dmitry Shubov Consulting developed a commercial advisory framework to address the legal and transactional friction Asian software and legaltech startups encounter when forming American entities, assigning cross-border intellectual property, and navigating U.S. venture capital diligence.

The advisory outlines three operational priorities for founders executing an American expansion:

*Delaware Flip Structuring: Reorganizing domestic operating entities under a U.S. Delaware parent corporation to meet the corporate governance and tax standards typically required by American institutional investors.

*Dual-Jurisdiction IP Assignment: Securing bilateral intellectual property assignments between overseas engineering hubs and the U.S. parent entity to reduce the risk of chain-of-title disputes during institutional diligence.

*CFIUS and Regulatory Alignment: Conducting proactive ownership reviews to help align foreign cap table structures with U.S. Committee on Foreign Investment regulations and federal data security mandates.

"Expanding into the U.S. is rarely a product problem for Southeast Asian founders. The traction is already there. It is usually just an administrative adjustment. American investors are used to very specific corporate setups, so getting your Delaware parent entity and IP assignments squared away early on removes friction and lets the business speak for itself," said Dmitry Shubov, Founder and CEO of Dmitry Shubov Consulting.

Navigating cross-border venture capital and U.S. market entry requires structural alignment well ahead of initial investor discussions. Dmitry Shubov Consulting advises Southeast Asian technology leaders and investor syndicates on structuring market expansions, helping position corporate entities for U.S. capital integration. For more information, please visit dmitryshubovconsulting.com.

About Dmitry Shubov Consulting

At Dmitry Shubov Consulting, our mission is to connect accredited investors with groundbreaking legal technology startups, fostering innovation and growth across Southeast Asia and helping Asian businesses enter the U.S. market. For more information, please visit our website or contact us directly.

Copyright 2026 GlobeNewswire, Inc.

First smartphone to run HarmonyOS 7 and include chip design breakthrough LogicFolding

SHENZHEN, CHINA - Media OutReach Newswire - 28 September 2026 - Huawei released the HUAWEI Mate XT 2 | ULTIMATE DESIGN trifold smartphone on September 7. The phone is the first to run HarmonyOS 7, and is the slimmest and largest foldable smartphone in the industry. The Mate XT 2's Kirin 9050 chip also includes a major breakthrough in semiconductor design.

As the first smartphone to feature the LogicFolding Tau (τ) Chip, the Mate XT 2 marks the chip's official entry into mass commercialization.

World-class engineering and design

The device is proving popular with consumers due to its foldable wing-like form, which means it can be opened up, transforming the phone into a tablet.

The engineering to make this possible is unprecedented. The glass screen must be tough enough to withstand daily use, whilst being able to fold thousands of times. The hinge to allow the screen to fold is the first of its kind. Once open, the handset is just 3.5mm thick. However, the screen is not the only remarkable folding technology in the device.

The first chip with semiconductor design breakthrough, LogicFolding

The Mate XT 2 Ultimate Design includes a major breakthrough in semiconductor design. The phone is the first to use Huawei's LogicFolding Tau chip Kirin 9050 Pro. Designed by engineers in Huawei's HiSilicon team, the chip offers a solution to the problem of geometric scaling.

With Moore's law (the historical observation that the number of transistors on a microchip doubles approximately every two years) believed to be reaching its physical limit, making chips smaller is becoming more challenging and costly.

For Huawei, faced with external restrictions, the need to find a solution came sooner than expected.

In May this year, He Tingbo, President of Huawei's HiSilicon division, unveiled a new way of designing and making chips, alongside a new law to measure their performance, the τ (Tau) Scaling Law. The work led to Ms He being recently named one of the world's leading AI innovators by Time Magazine.

The point of shrinking transistors was never the smallness itself, it's what the smallness delivered. Shoppers looking to buy the latest smartphone don't care if the chips inside have 7, 5 or even 2-nanometer nodes, they care about the performance of the device in their hands. What matters to consumers is the time it takes for a task to be completed, a video to be shared or a game to load. The performance of the chip should be measured in the same way: by time, not size. This is why Huawei proposed τ (Tau) Scaling Law as an alternative to Moore's Law.

Breaking through barriers to improve performance

The Kirin 9050 Pro uses 3D integration to boost performance. Traditional chip advancement focussed on packing more and more transistors into a linear plain by making each one smaller. LogicFolding uses 3D integration to reduce the distance between transistors by stacking them on top of one another, increasing the number of transistors whilst reducing the distance between them.

In fact, in the Kirin 9050 Pro transistor density has risen from approximately 155 to 238 million transistors per square millimetre. That's an equivalent increase to what was achieved in the previous three years using geometric shrinking.

It was thought that stacking active transistors on top of each other and sealing them inside a solid mobile device would present an engineering challenge. Power turns into heat, which in a confined space would raise the temperature and ultimately break the device.

The key to the solution came in recognising that integrated chips have both transistors and circuits. As He Tingbo explains in her IEEE article, Huawei's τ Chip Was Supposed to Melt?, the inner workings of a chip can be compared to an office worker's day of work. Many office workers will use more energy on their commute to and from the office than they do at their desk because they are moving around more on the road. The 'work' part of their day is not the most energy intensive part as they are often seated at their desk.

The same is true for chips. The most energy intensive part of the process is the 'commute', moving data from point A to point B, not processing it. Integrated circuits use power in two main ways. The first is switching, flipping a transistor gate to change a bit from 0 to 1 and back. The second is the transmission of that data, moving the bits from one part of the chip to another.

This is important in mobile phones where a lot of performance requirements are asked of a single chip. Equally, however, in a large AI cluster 80% of the energy is used in the moving the data, not processing it. In both cases, LogicFolding reduces the space between transistors which in turn reduces the power used. The previous assumption that packing transistors on top of one another would increase the heat turned out to be false. In fact, even with a higher transistor density per millimetre, LogicFolding chips run cooler per unit of work. The result is Huawei's most powerful smartphone ever.

The first phone to run HarmonyOS 7

The Mate XT 2 is the first smartphone to run HarmonyOS 7. Forty-two percent more powerful than the previous generation, it remains the slimmest and largest foldable display in the industry when open. The cover screen spans 6.5 inches, boosting the screen-to-body ratio from 86.4% to 92.8%. Enhanced with 70% better anti-reflection, the screen exhibits a deeper, cleaner black when off, and pure, crystal-clear transparency when lit.

The Huawei Mate XT 2 also introduces the world-first Smart Shield Privacy Screen on a foldable screen. Two independent pixel sets co-exist within the 10.2-inch display at a micro-pitch of just 9 μm. When Privacy Mode is activated, the screen seamlessly switches from a wide viewing angle to a narrow one while maintaining identical resolution and clarity, protecting your privacy in public spaces without compromising your view.

Industry first ECG analysis

Health tech is increasing important to consumers, and so the Mate XT 2 is the industry's first smartphone to introduce ECG analysis. Capitalising on the innovative tri-fold form factor, users can simply hold both side frames with both hands while unfolded to capture a 30-second ECG signal. Paired with the medically certified analysis software, it generates detailed ECG reports to help identify Sinus Rhythm, Atrial Fibrillation, and Premature Beats.

The launch of the Mate XT 2 marks a significant moment in Huawei's journey. The company's R&D has delivered industry leading, and industry changing innovation. More than half of Huawei's employees work in R&D. That's over 100,000 people. The company currently holds 160,000 active patents worldwide. In the first half of 2026 alone, Huawei's R&D investment was over RMB 121 billion, accounting for 25.94% of revenue, up 25.2% year on year.

The HUAWEI Mate XT 2 | ULTIMATE DESIGN starts at RMB 19,999 and is now available for purchase, along with a stylus set, following its official sales launch at 10:08 on September 12th.

The issuer is solely responsible for the content of this announcement.

Hashtags: #Huawei

MONACO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- The transition towards lower-carbon shipping and yachting was at the center of the 31st Captains' Forum at the Yacht Club de Monaco, bringing together captains, shipowners, fleet managers, shipyards, engineers and industry experts to examine the technologies and operational changes shaping the future of maritime energy.

Held under the theme 'Future Energy Sources Onboard Ships and Yachts', the forum, supported by Oceanco, MB92 Group, ICON Yachts and Jutheau Husson, addressed international regulations, alternative fuels, energy efficiency, vessel conversion and emerging propulsion technologies. The discussions highlighted that the energy transition is not based on a single solution, but on a combination of technologies, operational choices and the ability to adapt existing vessels.

The discussions also looked at a broad range of alternative energy sources and fuels, including HVO (hydrotreated vegetable oil), ammonia and hydrogen-derived fuels such as methanol, as well as hydrogen itself. Nuclear power was also discussed as a potential long-term option for certain types of maritime applications, highlighting the wide range of technologies being considered as the industry looks for alternatives to conventional fossil fuels.

Nicolas Millot, Chairman of the France Branch of the Nautical Institute, highlighted the growing regulatory documentation on commercial shipping and the need for the yachting sector - owners and crews - to get ready and work together to reduce emissions. "We need to understand" the regulations, he said, while also looking at measures such as changing fuels, weather routing and adapting vessel operations. For yachts, which are not subject to the same IMO requirements as merchant vessels, voluntary initiatives such as the Yacht Club de Monaco's SEA Index can provide an alternative framework for measuring and improving environmental performance.

The forum also explored the potential of refitting and converting existing vessels rather than building new ones. Marek Hasenkopf, Business Development Manager at Icon Yachts, said an existing vessel can have a "structural and also environmental advantage" over a new build. In one conversion project, 95% of the existing hull and superstructure were reused, representing around 2,900 tons of steel and avoiding the emissions associated with producing new material.

For Jean Guyon, CEO of Aeroforce, the future can go further. "We decided to go very, very far into 100% electric," he said, describing the company's MODX 70 catamaran, which combines solar power, battery storage and automated wing sails capable of generating electricity while sailing.

Technology, however, must also be usable by those operating the vessels. "Captains are very important," Guyon said. "They need to be very confident that it's working" and properly trained to use new systems.

The forum ultimately positioned the energy transition as a collective effort, bringing regulation, technology, shipbuilding and onboard experience together to reduce emissions and support cleaner maritime operations.

Copyright 2026 GlobeNewswire, Inc.

MONACO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- With more than 17,000 islands, hundreds of ethnic groups and one of the world's richest marine environments, Indonesia sees maritime tourism as a major opportunity for the country's future.

That ambition brought H.E. Widiyanti Putri Wardhana, Minister of Tourism of the Republic of Indonesia, to the Monaco Smart & Sustainable Marina Rendezvous, where she opened the sessions earlier in the week and presented Indonesia's vision for developing a stronger and more sustainable maritime tourism sector.

But the scale of the Indonesian archipelago also creates a complex challenge: developing maritime tourism requires infrastructure, skills, safety standards and a coordinated approach to sustainability across a vast and diverse territory.

"I feel like there is a lot of potential. That's why we are here today to learn from Monaco," the Minister said. For Indonesia, the Monaco event provided an opportunity to explore how an established maritime hub approaches innovation, infrastructure and sustainability. The two-day rendezvous brought together professionals from 30 nationalities and addressed issues ranging from biodiversity and investment to shore power, artificial intelligence, cybersecurity and the transformation of existing marina infrastructure.

Wardhana highlighted human capital development and training as key priorities for international cooperation. But Indonesia's ambitions extend beyond individual marinas, with the country also working towards a broader master plan for maritime tourism that brings together infrastructure, sustainability, safety and professional skills.

"We have a vision to have Indonesia tourism and maritime tourism to be the best destination in Asia," Wardhana said. The country is looking to Monaco as a source of expertise and international connections that could help accelerate the development of its own maritime tourism ecosystem.

"Hopefully, with this transformation and the expertise that we have gained here at the event, we will have a lot of collaboration in training, human capital development in the yachting industry, as well as sustainability efforts, safety, and the creation of a master plan for maritime tourism in Indonesia."

Monaco has positioned itself as a hub for sustainable innovation in yachting, with the Yacht Club de Monaco playing a key role in promoting this vision internationally. For Indonesia, the goal is ultimately to transform its extraordinary maritime resources into high-quality tourism destinations while creating greater benefits for local communities and environment.

For more information:

Press Office LaPresse - ufficio.stampa@lapresse.it

Copyright 2026 GlobeNewswire, Inc.

Latest Michelin Guide distinctions span hotels and restaurants in Thailand, Japan, the Philippines, and the UAE, reflecting the breadth of Dusit's hospitality offering

BANGKOK, THAILAND - Media OutReach Newswire - 28 September 2026 -Dusit Hotels and Resorts, the hotel arm of Dusit International, one of Thailand's leading hotel and property development companies, is celebrating continued Michelin recognition across its international portfolio, spanning distinctive hotel stays and dining experiences across multiple brands and markets.

Leading the latest honours is Dusit Thani Bangkok, Dusit's reimagined flagship hotel opposite Lumpini Park in the heart of the Thai capital, which has been elevated from One to Two Michelin Keys - denoting an exceptional stay - in the Michelin Guide's 2026 global hotel selection.

Rebuilt on the site of the original hotel, which opened in 1970 and closed for redevelopment in 2019, the 257-room property reopened in September 2024 as a key component of Dusit Central Park, a landmark mixed-use development bringing together the hotel, luxury residences, offices, retail, and an expansive rooftop park.

Conceived to set a new benchmark for the Dusit Thani brand, Dusit Thani Bangkok presents a contemporary interpretation of its predecessor's distinctive identity, with all guest rooms offering sweeping views of Lumpini Park. The hotel reflects a broader evolution of Dusit's luxury offering, centred on combining the group's Thai hospitality heritage with contemporary design and highly personalised service, while shaping each property's experiences around its destination.

This approach is reflected to award-winning effect elsewhere in Dusit's global portfolio. Dusit Thani Kyoto in Japan and Dusit Thani Mactan Cebu Resort in the Philippines have each retained One Michelin Key - denoting a very special stay - maintaining Dusit's Michelin Key presence across three countries while demonstrating how the brand's Thai-inspired gracious hospitality can take distinct forms in different locations.

Beyond its Michelin Key properties, ASAI Bangkok Chinatown, ASAI Bangkok Sathorn, and ASAI Kyoto Shijo - all part of Dusit's locally focused lifestyle brand, ASAI Hotels - are also included in the Guide's curated hotel selection, comprising properties chosen by Michelin's inspectors for their quality, individual character, and connection to their destinations.

Michelin recognition also extends to Dusit's dining experiences. At Dusit Thani Bangkok, Cannubi by Umberto Bombana holds One Michelin Star in the Michelin Guide Thailand 2026 - making it the only Italian restaurant in Thailand to hold the distinction. The contemporary Italian restaurant received its first Star when the 2026 edition was announced in November 2025.

Elsewhere in Bangkok, Thien Duong, the Vietnamese restaurant at Baan Dusit Thani, retains its Michelin Bib Gourmand, recognising good-quality, good-value cooking.

In the Philippines, Benjarong, serving refined Thai cuisine, and Umu, specialising in Japanese dining, at Dusit Thani Manila are both included as Michelin Selected restaurants in the Michelin Guide Philippines 2026.

In the UAE, Namak, serving contemporary Indian cuisine at Dusit Thani Abu Dhabi, continues its run as a Michelin Selected restaurant.

Collectively, the Michelin recognition spans multiple Dusit brands, destinations, and hospitality experiences, from luxury and lifestyle hotels to a diverse range of dining concepts.

"Receiving Two Michelin Keys for Dusit Thani Bangkok is a tremendous honour, and one made even more meaningful by the wider Michelin recognition our hotels and restaurants continue to receive across several destinations," said Chanin Donavanik, Group CEO, Dusit International. "These achievements belong first and foremost to our teams, whose skill, creativity, and care shape the experiences our guests enjoy every day. They also affirm our belief that staying true to our Thai hospitality heritage while continually evolving for the needs of today's travellers can create experiences that resonate far beyond our home market. We are immensely proud of what our teams have achieved, and we will continue building on this foundation across our portfolio."

High-resolution images and a short video accompanying this media release are available here: Dusit celebrates Michelin recognition

For more information about Dusit Hotels and Resorts, please visit dusit.com.

About Dusit Hotels and Resorts

Dusit Hotels and Resorts is the hotel arm of Dusit International. With a heartfelt belief and commitment to introducing Thai-inspired gracious hospitality to the world, Dusit Hotels and Resorts offers guests a uniquely special stay in high-style surroundings and a personalised approach to service. The group's portfolio of hotels, resorts and luxury villas includes close to 300 properties operating under a total of nine brands (Devarana ? Dusit Retreats, Dusit Thani, Dusit Suites, Dusit Collection, Dusit Hotels, dusitD2, Dusit Princess, ASAI Hotels, and Elite Havens) across 19 countries worldwide.

For more information, please visit dusit.com

About Dusit International

Established in 1949, Dusit International is a leading hospitality group listed on the Stock Exchange of Thailand. Its operations comprise five distinct yet complementary business units: Dusit Hotels and Resorts, Dusit Hospitality Education, Dusit Foods, Real Estate Development, and Hospitality-Related Services.

Dusit's diversified investments in real estate development, hospitality-related services, and the food sector are part of its long-term strategy for sustainable growth, which focuses on three key areas: balance, expansion, and diversification.

For more information, please visit dusit-international.com

The issuer is solely responsible for the content of this announcement.

Hashtags: #Dusit

*Acquisition diversifies durable cash flows and advances Zymeworks' strategy to build a productive R&D company with a growing portfolio of revenue-generating assets

*YUPELRI expected to contribute immediately accretive revenue and cash flow to Zymeworks with base case mid-teens IRR

*Zymeworks to retain existing commercial organization supporting YUPELRI hospital promotion

*The Company expects total revenue, including collaboration revenue from YUPELRI, for 2026 to be between $278 million and $292 million and 2026 Adjusted EBITDA to be between $114 million and $128 million

*Conference call with Zymeworks management today at 8:30 am Eastern Time (ET)

VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) --  Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the final transaction details and updated financial guidance following the completion of its acquisition of Theravance Biopharma.

The acquisition adds YUPELRI (revefenacin) to Zymeworks' portfolio, providing a durable, recurring source of cash flow to fund the Company's long-term growth strategy. Through Theravance Biopharma's collaboration with Viatris, Zymeworks is entitled to a 35% share of net U.S. profits from YUPELRI and royalties on net sales outside the United States. In the first half of 2026, total YUPELRI sales of $133.1 million resulted in collaboration revenue to Theravance Biopharma of $38.4 million.

"Zymeworks is uniquely positioned to create value from the acquisition through our existing R&D and operational infrastructure, including the ability to leverage the acquired Irish tax attributes alongside our ongoing R&D activities in Ireland, opportunities that are not readily available to traditional royalty-focused buyers," said Scott Platshon, Chief Business Officer at Zymeworks. "We are pleased to welcome the Theravance Biopharma team to Zymeworks and bring together differentiated assets that add meaningful sources of cash flow to our business. We look forward to building on the combined organizations' strengths as we continue to build a durable, diversified business and work to develop innovative medicines for patients with serious diseases."

Commercial Organization and Integration

Zymeworks intends to retain the current commercial organization responsible for YUPELRI sales through the hospital channel. The team brings established commercial capabilities and relationships that Zymeworks believes can support continued growth of the product within the combined organization. The Company plans to hire a seasoned pharmaceutical executive with experience building and leading commercial pharmaceutical organizations to lead the commercial operations of Theravance Biopharma.

In addition, Stuart Knight will become Executive Vice President and Chief Information Officer of Zymeworks, where Stuart will guide the Company's future technology strategy, including continued investment in the Company's existing AI, machine learning, and data science capabilities. Stuart brings substantial experience in biotech and pharmaceutical companies operating in both the United States and Europe. Stuart will also be joined by Jesse Fecker, Ph.D., J.D., who joins Zymeworks as Vice President, Intellectual Property.

"We are very pleased to have Stuart and Jesse join Zymeworks' leadership team as they both bring additional experience and capabilities that will be helpful as we execute against our long-term strategic objectives," said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.

Zymeworks also retains ownership of Theravance Biopharma's research and development assets, which will be evaluated in the context of the Company's broader pipeline, strategic priorities, and disciplined capital allocation framework. The Company will continue to pursue opportunities to maximize the value of its combined R&D engine through partnerships, collaborations and other strategic structures, including the potential externalization of selected programs where appropriate.

Financial Impact of Theravance Biopharma Acquisition

The acquisition is expected to provide Zymeworks with meaningful and immediate incremental revenue and operating cash flow following closing, including:

Mid-teens base-case IRR, supported primarily by growth in YUPELRI revenues and a smaller contribution from VIBATIV?. This base case does not include potential upside contributions from utilization of tax attributes or future R&D or business development opportunities.

25% growth in YUPELRI hospital sales in the second quarter of 2026, supporting continued margin expansion and increasing operating leverage as net sales continue to scale. Hospital channel growth remains a key driver of the product's continued expansion in the community setting.

Acquisition and restructuring-related costs, excluding capitalized costs attributed to the OMERS Life Sciences (OMERS) non-recourse financing, of approximately $25-30 million

$2.5 billion of Irish tax attributes, which may provide additional flexibility to generate value from future Irish revenues, IP structuring and potential acquisitions or investments through the Company's existing Irish R&D operations. No value has been assigned to the utilization of these tax attributes in the transaction valuation or base case IRR, and any future utilization would therefore represent additional upside.

Potential $100 million TRELEGY ELLIPTA milestone payment expected in the first quarter of 2027, assuming milestone conditions met, offsetting cash outlay for the purchase price.

Transaction Details

Under the terms of the merger agreement announced on June 29, 2026, Theravance Biopharma shareholders received $17.00 in cash at closing for each share of Theravance Biopharma common stock.

The acquisition was financed through a $350 million non-dilutive, non-recourse note from OMERS, in which 75% of the YUPELRI profit-share cash flows are contractually assigned to OMERS to service the associated debt obligations. In addition, approximately $217.5 million of existing cash resources of Zymeworks was used to finance the remaining purchase price, after utilizing the available cash acquired from Theravance Biopharma. The Company expects this net investment to be reduced upon receipt of a potential milestone payment related to TRELEGY ELLIPTA of $100 million expected in the first quarter of 2027.

During the one-year period from closing of this transaction, a designee of Theravance Biopharma will seek to potentially license, divest or otherwise monetize ampreloxetine, with no additional resources expected from Zymeworks. The economics of any such transaction will be shared 20/80 between Zymeworks and Theravance Biopharma shareholders.

Following completion of the transaction, Theravance Biopharma's common stock is no longer listed for trading on the Nasdaq Global Select Market.

Accounting Treatment

The transaction is expected to be accounted for as a business combination. The purchase price will be allocated to the fair value of the net assets acquired and primarily includes rights related to YUPELRI, with any remaining amount recorded as goodwill. YUPELRI is expected to represent the principal identifiable intangible asset and will be amortized over its estimated useful life, generally through the expected loss-of-exclusivity period.

The right to receive a potential milestone payment based on global net sales of TRELEGY ELLIPTA is expected to be recognized as a financial asset at fair value as of the closing date. Assuming the applicable commercial sales milestone is achieved by December 31, 2026, the related milestone payment of $100 million is expected to be collected in the first quarter of 2027. 

The Company also expects to recognize a tax liability due to an uncertain tax position as part of the accounting for the business combination. Upon expiration of the applicable audit period in October 2026, the liability may be reversed, resulting in the recognition of a non-cash income tax benefit in the fourth quarter of 2026.

The Company expects to account for the $350 million non-recourse note issued to OMERS as debt using the prospective effective interest rate method. Until the note is repaid, 75% of the YUPELRI profit-share cash flows will be applied to the payment of principal and interest, with the Company retaining the remaining 25%. Following repayment of the note, the Company will retain 100% of the YUPELRI profit-share cash flows.

The preliminary accounting for the transaction will be reflected in the Company's consolidated financial statements in its Form 10-Q for the quarter ending September 30, 2026, which is expected to be filed in November 2026.

Updated Financial Guidance for 2026

With the completion of the Theravance Biopharma acquisition and the receipt of the U.S. Food and Drug Administration approval of Ziihera? (zanidatamab-hrii) for first-line HER2-positive advanced gastroesophageal adenocarcinoma on August 25, 2026, the Company has provided updated financial guidance utilizing relevant financial metrics that it believes provide a more suitable framework for evaluating operating performance of the business.

"The Company expects total revenue for 2026 to be between $278 million and $292 million and 2026 Adjusted EBITDA to be between $114 million and $128 million, excluding the impact of any future transactions," stated Kristin Stafford, Chief Financial Officer of Zymeworks.

"During 2026, we have been able to access a total of $600 million in non-dilutive financing in the form of non-recourse notes at an attractive cost of capital, with proceeds being utilized to fund both the Theravance Biopharma acquisition and continued share repurchases. Our financing strategy and the share repurchase program have focused on minimizing equity dilution to our shareholders. We completed our last public equity offering in January 2022 and have no current plans for additional equity issuances."

Adjusted EBITDA is a non-GAAP financial measure. See "Note Regarding Use of Non-GAAP Financial Measures" below for an explanation of these measures. A reconciliation between GAAP reported and non-GAAP financial information for historical results is provided at the end of this earnings release.

Zymeworks 2026 Share Repurchase Program

In May 2026, the Board of Directors authorized a 2026 share repurchase program under which the Company may repurchase up to $125.0 million of its outstanding common stock, par value $0.00001 per share. As of September 28, 2026, the Company has utilized approximately $49.3 million of this current approved repurchase program to acquire 1,971,454 shares at an average price of $25.04 per share (exclusive of commission expense and estimated excise tax).

Since initiating its share repurchase program in August 2024, the Company has cumulatively utilized $211.6 million to reacquire 10,571,316 shares at an average price of $20.02 per share (exclusive of commission expense and estimated excise tax). As of September 14, 2026, the Company had approximately 71.2 million common shares outstanding.

Investor Call Details

Zymeworks will host a conference call today with investors and the general public at 8:30 am ET. Dial-in details and webcast link are available on Zymeworks' website at https://ir.zymeworks.com/events-and-presentations. A replay of the webcast will be available within 24 hours following the conclusion of the call and will remain archived for a limited period.

About Zymeworks Inc.

Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. Zymeworks' asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI (revefenacin), with a differentiated internal research and development engine. Zymeworks' portfolio also includes Ziihera (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks' proprietary antibody engineering technologies.

Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. These capabilities, together with Zymeworks' integrated drug development expertise, enable Zymeworks to develop differentiated therapeutics and create value through both internal innovation and strategic partnerships.

For more information about Zymeworks, its portfolio and pipeline, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the anticipated benefits of the acquisition of Theravance Biopharma; the anticipated benefits of the financing in connection with the closing of the acquisition; anticipated milestones payments; Zymeworks' ability to utilize Irish tax attributes; Zymeworks' flexibility to invest in its R&D pipeline and pursue strategic opportunities while returning capital to stockholders; future growth of YUPELRI sales and future royalty payments; sales and future royalty payments related to VIBATIV; contingent milestone payments due to Theravance Biopharma from the sale of Theravance Biopharma's TRELEGY ELLIPTA royalty interests; the repayment of the non-recourse note issued to OMERS Life Sciences; Zymeworks' expectations regarding implementation of its long-term strategy to maximize value creation; Zymeworks' and its partners' clinical development of product candidates; potential safety profile and therapeutic effects of product candidates; the commercial potential of technology platforms and product candidates; the anticipated benefits of its collaboration agreements; the Company's 2026 full year guidance and other information that is not historical information. When used herein, words such as "plan", "believe", "expect", "may", "continue", "anticipate", "potential", "will", "on track", "progress", "preserve", "intend", "could", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking.

All forward-looking statements are based upon Zymeworks' current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: risks related to the financing in connection with the closing of the acquisition; any of Zymeworks' or its partners' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; uncertainties regarding the commercial success of YUPELRI, TRELEGY and VIBATIV; the anticipated benefits of the acquisition may not be realized or will not be realized within the expected time period; TRELEGY may not achieve anticipated sales resulting in sales milestones not being met; Zymeworks may not achieve milestones or receive additional payments or royalties under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks' business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks' behalf; zanidatamab may not be successfully commercialized; Zymeworks' business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks' evolution of its business strategy may not deliver meaningful stockholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue-generating assets alongside its active R&D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates; data providing early validation of our antibody drug conjugate platform and next generation pipeline programs may not be replicated in future studies; Zymeworks' assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; the inability of Zymeworks to identify and consummate a strategic acquisition; and the factors described under "Risk Factors" in Zymeworks' quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Explanation of Non-GAAP Financial Information

In addition to reporting financial information in accordance with U.S. generally accepted accounting principles (GAAP) in this press release, the Company has elected to present Adjusted EBITDA, a non-GAAP financial measure, on a forward-looking basis. Zymeworks believes Adjusted EBITDA provides useful information regarding the Company's underlying operating performance and facilitates comparisons of operating results across periods.

Adjusted EBITDA should be considered in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP. Other companies may calculate Adjusted EBITDA differently or may use other measures to evaluate their performance. Investors and others are encouraged to review Zymeworks' financial information in its entirety and not rely on a single financial measure.

Adjusted EBITDA is calculated as net income (loss), adjusted to exclude income tax expense or benefit, interest income and expense, depreciation and amortization, other non-operating income or expense, share-based compensation expense, and certain other items, including transaction-related costs, restructuring charges and severance costs. A reconciliation of Adjusted EBITDA to net income (loss), its most directly comparable GAAP financial measure, is included in the tables at the end of this press release.

A reconciliation of forward-looking Adjusted EBITDA to the most directly comparable GAAP measures is not available without unreasonable effort due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Accordingly, in reliance on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K, we have not provided a reconciliation of forward-looking Adjusted EBITDA provided in this press release.

For the same reasons, the Company is unable to address the probable significance of the unavailable information. The Company provides non-GAAP financial measures that it believes will be achieved; however, it cannot accurately predict all of the components of the adjusted calculations, and the GAAP measures may be materially different than the non-GAAP measures.

Three Months Ended June 30,						Six Months Ended June 30,
		2026			2025			2026			2025
Net income (loss)	$	(45.0	)	$	2.3		$	(89.2	)	$	(20.3	)
Adjustments:
Income tax benefit / (expense)		(0.3	)		(0.2	)		(2.5	)		0.3
Interest expense / (income), net		3.3			(3.4	)		2.7			(6.9	)
Depreciation and amortization		1.1			2.5			2.3			5.1
Other non-operating (income) / expense, net		(0.2	)		0.6			(0.3	)		0.6
Share-based compensation expense		11.3			5.9			18.3			12.3
Transaction-related costs		3.0			?			3.0			?
Restructuring and severance costs		0.1			0.7			3.4			1.2
Adjusted EBITDA	$	(26.7	)	$	8.4		$	(62.3	)	$	(7.7	)

Copyright 2026 GlobeNewswire, Inc.

The live account trading competition runs from 28 September to 31 October 2026 and is open to beginner and experienced traders alike, with a minimum starting equity of USD 100.

JAKARTA, Indonesia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- EBC Financial Group (EBC) announces the launch of the EBC Live Trader Cup Indonesia, a live account trading competition taking place from 28 September to 31 October 2026.

Under the theme "Buktikan Skill Tradingmu, Rebut Gelar Juara!", this event empowers Indonesian traders to demonstrate and refine their trading expertise in authentic market conditions.

Traders can trade both forex and local favourites such as gold (XAUUSD) and compete for a chance to be among the Top 10 participants, winning from a total prize pool of up to IDR 40 million.

The competition period coincides with a series of US economic releases that often move global markets, especially the gold price. The September Non-Farm Payrolls (NFP) report is scheduled for 2 October, followed by the Consumer Price Index (CPI) inflation data on 14 October. The highlight is the Federal Reserve's Federal Open Market Committee (FOMC) meeting on 27 to 28 October, with the interest rate decision announced in the early hours of 29 October, Western Indonesian Time (WIB).

For gold traders, these market-moving events present an exceptional opportunity to test their skills and strategies. Navigating the volatility brought on by NFP and FOMC releases requires careful preparation, a deep understanding of economic data and its implications, and a disciplined approach to risk management.

An Arena to Test Gold Trading Strategies

Participants are free to apply their own approach. Options range from XAUUSD scalping strategies on lower timeframes and XAUUSD SMC (Smart Money Concepts) strategies, now popular in trading communities, to classic XAUUSD support and resistance analysis. No single XAUUSD timeframe works for everyone; what matters is how consistently traders execute their own plans.

The timing is important as well. Many traders prefer trading gold during the London session, which opens at around 14:00 WIB, or the New York session in the WIB evening, when volume and volatility typically rise. The overlap between the two sessions is often the busiest window for XAUUSD traders in Indonesia.

The competition also addresses a common question among aspiring traders: what is the minimum capital required to start trading gold? Participants can join with a starting capital of USD100. Ranking is based on percentage returns, not total profit. This allows traders with smaller accounts to compete on a level playing field.

The competition also answers a question beginners often ask: what is the minimum capital for gold trading? Participants need only USD 100 in equity to join. Because rankings are based on percentage return rather than nominal profit, small accounts start on equal footing with large ones.

For those just learning how to trade gold, understanding contract size is an important first step. One lot of XAUUSD is generally equivalent to 100 troy ounces of gold, so lot sizing and knowing how to calculate XAUUSD pips largely determine the risk on each position.

Fair for Every Account Size

Rankings are determined by return rate: trading results relative to equity at registration plus deposits made during the competition. Additional deposits mid-competition increase the denominator, so they do not automatically boost a ranking. Withdrawals, on the other hand, do not affect the calculation. All winners must finish with a positive final return.

Every participant will share their trading signals within the EBC copy trading community. This transparent approach enables beginners to observe and learn directly from more experienced traders, especially during pivotal moments such as the NFP and FOMC releases.

"October will be packed with catalysts for the gold market, and that is exactly when a trader's skill shows. Through the Live Trader Cup, we want to provide a fair arena where discipline and strategy matter more than account size," said Fikri Fairuz, Marketing Manager at EBC Financial Group Indonesia.

"We encourage participants to view this competition as a valuable opportunity for growth, skill enhancement, and professional development. In our experience, the most successful traders are defined not by the risks they take, but by their ability to achieve consistent, sustainable growth," he added.

How to Join

Register through the EBC User Portal by clicking "Register Now" on the campaign page. Use a new or existing PRO or STD live account with at least USD 100 in equity, no open positions, and no active copy trades. Each participant may register up to 10 accounts but is eligible for only one prize.

Prizes are USD 1,000 (1st place), USD 500 (2nd), USD 300 (3rd), USD 100 (4th?5th) and USD 50 (6th?10th). They are credited within 30 business days after the competition ends.

Full details at https://ebcidn.com/live-trading/id/

Disclaimer: This material is for information only and does not constitute a recommendation or advice from EBC Financial Group and all its entities ("EBC"). Trading Forex and Contracts for Difference (CFDs) on margin carries a high level of risk and may not be suitable for all investors.

Losses can exceed your deposits. Before trading, you should carefully consider your trading objectives, level of experience, and risk appetite, and consult an independent financial advisor if necessary. Statistics or past investment performance are not a guarantee of future performance. EBC is not liable for any damages arising from reliance on this information.

About EBC Financial Group

EBC Financial Group, headquartered in London, UK, is a comprehensive financial services group licensed and operating in multiple key jurisdictions worldwide. The group offers over 200 Contracts for Difference (CFDs) products, including foreign exchange, precious metals, energy, stock indices, US stocks, ETFs, and cryptocurrencies. With branches in major global financial centres such as Tokyo, Sydney, Singapore, and Hong Kong, its service network covers over 100 countries and regions.

Regulation is the cornerstone of trust in the financial industry. EBC 's various operating entities hold financial regulatory licenses issued by the UK's Financial Conduct Authority (FCA), Australia's Securities and Investments Commission (ASIC), the Cayman Islands Monetary Authority (CIMA), and South Africa's Financial Sector Conduct Authority (FSCA), strictly adhering to local regulatory rules in their operations.

Leveraging its FCA-regulated liquidity access, EBC has established long-term and stable partnerships with over 50 leading banks and non-bank liquidity providers globally. By integrating clearing-grade liquidity quotes, EBC provides clients with direct access to the primary liquidity market, delivering highly competitive institutional-grade liquidity depth and bank-level spreads, allowing clients to easily enjoy extremely low transaction costs. All clients within the group can enjoy top-tier liquidity access through its FCA license; even for offshore accounts, quotes and orders are ultimately processed by a UK company.

Combining big data and AI algorithms to optimize order matching mechanisms, EBC achieves over 87.6% of its orders executed at more favourable prices. For high-frequency and high-volume traders, EBC offers the customized EBC Private Room, a dedicated segregated trading channel that conceals trading orders and avoids market order manipulation. EBC is also one of the few licensed brokers in the industry capable of providing qualified professional investors with FCA liquidity clearing accounts with leverage up to 100x.

The Group's core management team has over 30 years of experience working in large global financial institutions, having gone through multiple complete financial cycles. They have held core management positions in institutions regulated by the FCA, SEC, and CFTC, and their expertise covers key areas such as brokerage business, operations management, compliance and governance, and corporate risk management.

EBC has been named World Finance's "Best Broker in the World" for four consecutive years, earning the trust of over 5 million registered users worldwide. Upholding a long-term perspective, the Group actively fulfils its social responsibilities: as an official partner of FC Barcelona, it collaborates with the University of Oxford's Department of Economics to promote financial education, supports the UN Foundation's "United to Beat Malaria" project, and partners with the World Association of Girl Guides and Girl Scouts (WAGGGS) to advance women's empowerment and social equity.

EBC firmly believes that everyone who trades seriously deserves to be treated seriously.

https://www.ebc.com/  

Copyright 2026 GlobeNewswire, Inc.